SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:prod.swepub.kib.ki.se:149242675"
 

Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:149242675" > Genome-wide associa...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004670naa a2200817 4500
001oai:prod.swepub.kib.ki.se:149242675
003SwePub
008240701s2022 | |||||||||||000 ||eng|
024a http://kipublications.ki.se/Default.aspx?queryparsed=id:1492426752 URI
024a https://doi.org/10.1038/s41398-022-01884-32 DOI
040 a (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Okhuijsen-Pfeifer, C4 aut
2451 0a Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders
264 c 2022-04-07
264 1b Springer Science and Business Media LLC,c 2022
520 a Clozapine is the most effective antipsychotic for patients with treatment-resistant schizophrenia. However, response is highly variable and possible genetic underpinnings of this variability remain unknown. Here, we performed polygenic risk score (PRS) analyses to estimate the amount of variance in symptom severity among clozapine-treated patients explained by PRSs (R2) and examined the association between symptom severity and genotype-predicted CYP1A2, CYP2D6, and CYP2C19 enzyme activity. Genome-wide association (GWA) analyses were performed to explore loci associated with symptom severity. A multicenter cohort of 804 patients (after quality control N = 684) with schizophrenia spectrum disorder treated with clozapine were cross-sectionally assessed using the Positive and Negative Syndrome Scale and/or the Clinical Global Impression-Severity (CGI-S) scale. GWA and PRS regression analyses were conducted. Genotype-predicted CYP1A2, CYP2D6, and CYP2C19 enzyme activities were calculated. Schizophrenia-PRS was most significantly and positively associated with low symptom severity (p = 1.03 × 10−3; R2 = 1.85). Cross-disorder-PRS was also positively associated with lower CGI-S score (p = 0.01; R2 = 0.81). Compared to the lowest tertile, patients in the highest schizophrenia-PRS tertile had 1.94 times (p = 6.84×10−4) increased probability of low symptom severity. Higher genotype-predicted CYP2C19 enzyme activity was independently associated with lower symptom severity (p = 8.44×10−3). While no locus surpassed the genome-wide significance threshold, rs1923778 within NFIB showed a suggestive association (p = 3.78×10−7) with symptom severity. We show that high schizophrenia-PRS and genotype-predicted CYP2C19 enzyme activity are independently associated with lower symptom severity among individuals treated with clozapine. Our findings open avenues for future pharmacogenomic projects investigating the potential of PRS and genotype-predicted CYP-activity in schizophrenia.
700a van der Horst, MZ4 aut
700a Bousman, CA4 aut
700a Lin, B4 aut
700a van Eijk, KR4 aut
700a Ripke, S4 aut
700a Ayhan, Y4 aut
700a Babaoglu, MO4 aut
700a Bak, M4 aut
700a Alink, W4 aut
700a van Beek, H4 aut
700a Beld, E4 aut
700a Bouhuis, A4 aut
700a Edlinger, M4 aut
700a Erdogan, IM4 aut
700a Ertugrul, A4 aut
700a Yoca, G4 aut
700a Everall, P4 aut
700a Gorlitz, T4 aut
700a Grootens, KP4 aut
700a Gutwinski, S4 aut
700a Hallikainen, T4 aut
700a Jeger-Land, E4 aut
700a de Koning, M4 aut
700a Lahteenvuo, M4 aut
700a Legge, SE4 aut
700a Leucht, S4 aut
700a Morgenroth, C4 aut
700a Muderrisoglu, A4 aut
700a Narang, A4 aut
700a Pantelis, C4 aut
700a Pardinas, AF4 aut
700a Oviedo-Salcedo, T4 aut
700a Schneider-Thoma, J4 aut
700a Schreiter, S4 aut
700a Repo-Tiihonen, E4 aut
700a Tuppurainen, H4 aut
700a Veereschild, M4 aut
700a Veerman, S4 aut
700a de Vos, M4 aut
700a Wagner, E4 aut
700a Cohen, D4 aut
700a Bogers, JPAM4 aut
700a Walters, JTR4 aut
700a Yagcioglu, EA4 aut
700a Tiihonen, Ju Karolinska Institutet4 aut
700a Hasan, A4 aut
700a Luykx, JJ4 aut
710a Karolinska Institutet4 org
773t Translational psychiatryd : Springer Science and Business Media LLCg 12:1, s. 145-q 12:1<145-x 2158-3188
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:149242675
8564 8u https://doi.org/10.1038/s41398-022-01884-3

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy